[Tianyin Pharmaceutical Provides Update on Filing of Form 10-K for Fiscal Year Ended June 30, 2014 Currently the Company is working diligently with the auditor to finish the audit and complete the 2014 10-K, and expect to file the 2014 Form 10-K within two weeks. Under NYSE MKT rules, until the Company files its Form 10-K, its common stock will] []
[Tianyin Pharmaceutical Provides Update on Filing of Form 10-K for Fiscal Year Ended June 30, 2014 Currently the Company is working diligently with the auditor to finish the audit and complete the 2014 10-K, and expect to file the 2014 Form 10-K within two weeks. Under NYSE MKT rules, until the Company files its Form 10-K, its common stock will] []
[Form 6-K TABLE OF CONTENTS Page 3 4 2 WuXi PharmaTech (Cayman) Inc. Edward Hu Chief Financial Officer 3]
[WuXi PharmaTech (Cayman) Inc. Form 6-K Page 3 4 6 11 2 WuXi PharmaTech (Cayman) Inc.]
[WuXi PharmaTech (Cayman) Inc. Form 6-K Page 3 4 6 11 2 WuXi PharmaTech (Cayman) Inc.]
[Form 6-K TABLE OF CONTENTS Page 3 4 2 WuXi PharmaTech (Cayman) Inc. Edward Hu Chief Financial Officer 3]
[WuXi PharmaTech (Cayman) Inc. Form 6-K 3 4 2 WuXi PharmaTech (Cayman) Inc. Edward Hu Chief Financial Officer]
[BEIJING, Aug. 27, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, today announced the results of the Company's 2014 Annual General Meeting of Shareholders held on Wednesday, August 27, 2014 in Beijing, PRC. The required quorum, a majority of the common shares outstanding, was voted by proxy. The Company's shareholders approved the following] []
[BEIJING, Aug. 27, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, today announced the results of the Company's 2014 Annual General Meeting of Shareholders held on Wednesday, August 27, 2014 in Beijing, PRC. The required quorum, a majority of the common shares outstanding, was voted by proxy. The Company's shareholders approved the following] []
[Sinovac Receives Tender to Supply Inactivated Hepatitis A Vaccine Healive in Beijing Under Expanded Immunization Program BEIJING, July 21, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Health Bureau as the sole supplier of inactivated hepatitis A vaccine in pre-filled syringe dosage] [Sinovac Receives Beijing CDC Tender to Supply Seasonal Flu Vaccine Anflu BEIJING, July 23, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Centers for Disease Control and Prevention ("Beijing CDC") to be a supplier of the seasonal influenza vaccine to the citizens] [Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results BEIJING, July 25, 2014 -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the second quarter ended June 30, 2014, after market close on Thursday, August 14, 2014 EDT. The Company] []
